News
Invitation to a Pharma Industry Talk by Dr. Dirk Bredenbröker,
Executive Vice President Research and Development,
Schwabe Pharma, Karlsruhe
| When: | October 2nd 2024, 3 PM |
| Link: | https://hhu.webex.com/meet/nteusch |
| Title of the talk: | Introduction to the Schwabe Pharma Research & Development Model and Innovation Strategy for Phytomedicine |
| Organized by: | Prof. Dr. Nicole Teusch |
________________________________________________________________
Scientific Short Symposium on the occasion of Prof. Ming Ma's visit at HHU
24th July 2024
On the occasion of the visit of Prof. Ming Ma from the prestigious School of Pharmaceutical Sciences, Peking University, we organized a short scientific symposium. Prof. Ma was accompanied by colleagues from Peking University and about 25 selected students from the so-called Pharmaceutical Innovation Class. The School of Pharmaceutical Sciences at Peking University is ranked 1st in Pharmacy in China.
In addition to the scientific program Dr. Wegener-Feldbruegge, Head of the Welcome Center for International Researchers at HHU, introduced international funding opportunities and support provided by the Welcome Center.
07.06.2024
The Teusch research group is pleased to announce our new article entitled “Novel Histone Deacetylase (HDAC) Inhibitor Induces Apoptosis and Suppresses Invasion via E-cadherin Upregulation in Pancreatic Ductal Adenocarcinoma (PDAC)” which has been published in the journal Pharmaceuticals and is available online:
https://www.mdpi.com/1424-8247/17/6/752
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreatic cancer characterized by therapy resistance and early metastasis, resulting in a low survival rate. Histone deacetylase (HDAC) inhibitors showed potential for the treatment of hematological malignancies. In PDAC, the overexpression of HDAC 2 is associated with the epithelial–mesenchymal transition (EMT), principally accompanied by the downregulation of the epithelial marker E-cadherin and increased metastatic capacity. Our study indicates that the HDAC inhibitor acts by suppressing tumor cell invasion via upregulating E-cadherin mediated by HDAC 2 blockade and by inducing cell cycle arrest leading to apoptosis via HDAC 6 inhibition. Moreover, a synergistic interaction with the chemotherapeutic drug gemcitabine could be demonstrated suggesting that selective HDAC inhibitors might represent a novel strategy for combination therapies of PDAC tumorigenesis and metastasis.
________________________________________________________________
Fostering the 3R concept in drug discovery
24.04.2024
On April 24th Nicole Teusch had the pleasure of presenting a new 3D organoid-on-chip model developed in collaboration with Dynamic42 GmbH to the scientific advisory board of the set foundation (Foundation for the Promotion of Research on Alternative Methods to Animal Experiments).
An inspiring afternoon with many exciting discussions and new ideas on modern alternative methods in pharmaceutical research.
________________________________________________________________
New Publication
20.12.2023
Check out our recent publication in Marine Drugs in a Theme Issue Honoring Prof. Peter Proksch`s 70th Birthday: